“Study to evaluate perioperative circulating tumor DNA as prognostic biomarker in patients undergoing neoadjuvant therapy for resectable non-small cell lung cancer.” —TSOG 101
The aim of this study is to determine the validity of using quantitative ctDNA as a surrogate marker for pathologic treatment response in patients receiving neoadjuvant therapy for stage IIA-IIIB NSCLC who are undergoing curative-intent resection.
The second aim is to determine, in patients with NSCLC, the prognostic value of persistent ctDNA following curative-intent resection for predicting recurrence, disease-free survival, and overall survival.
The third aim is to correlate the percent change in levels of ctDNA to percent change in the SUVmax of the primary tumor on 18-FDG-PET scan before and after neoadjuvant therapy.
“Registry trial of active surveillance for multifocal ground glass opacities (GGOs).” —TSOG 102
The primary objective of this study is to determine lung cancer–specific survival at 5 years among patients undergoing active surveillance for GGOs.
The secondary objective is to determine the following endpoints among patients undergoing active surveillance for GGOs: overall survival, freedom from progression (any), freedom from nodal progression, freedom from distant progression, cumulative incidence of intervention (biopsy or resection), cumulative incidence of a new GGO, and cumulative incidence of confirmed lung cancer diagnosis.
“The role of multimodality management in risk-stratified patients with lung-limited metastatic colorectal cancer.” —TSOG 103
The primary objectives of this study are to compare recurrence-free survival in patients with “low-risk” lung-limited mCRC undergoing pulmonary metastasectomy with or without perioperative chemotherapy, as well as to compare overall survival in patients with “high-risk” lung-limited mCRC receiving systemic chemotherapy with or without surgical resection.
Additional exploratory objectives involve the evaluation of changes in ctDNA following surgical resection and/or systemic chemotherapy in patients with lung-limited mCRC.